Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models
| Autor: | Pei San Yee, Chai Phei Gan, Vyomesh Patel, Kein Seong Mun, Nur Syafinaz Zainal, Mannil Thomas Abraham, Zainal Ariff Abdul Rahman, Siti Mazlipah Ismail, Sok Ching Cheong, Bernard Kok Bang Lee |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Cancer Research Pyridones Afatinib Cell Apoptosis Mice SCID Pyrimidinones Mice 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Mice Inbred NOD ErbB Antineoplastic Combined Chemotherapy Protocols Tumor Cells Cultured Carcinoma Animals Humans Medicine Pharmacology (medical) Cell Proliferation Trametinib business.industry Cell growth MEK inhibitor Cell Cycle Drug Synergism medicine.disease Xenograft Model Antitumor Assays stomatognathic diseases 030104 developmental biology medicine.anatomical_structure Oncology chemistry 030220 oncology & carcinogenesis Carcinoma Squamous Cell Cancer research Female Mouth Neoplasms Growth inhibition business Signal Transduction medicine.drug |
| Zdroj: | Targeted Oncology. 14:223-235 |
| ISSN: | 1776-260X 1776-2596 |
| Popis: | Given that aberrant activation of epidermal growth factor receptor family receptors (ErbB) is a common event in oral squamous cell carcinoma, and that high expression of these receptor proteins is often associated with poor prognosis, this rationalizes the approach of targeting ErbB signaling pathways to improve the survival of patients with oral squamous cell carcinoma. However, monotherapy with the ErbB blocker afatinib has shown limited survival benefits. This study was performed to identify mechanisms of afatinib resistance and to explore potential afatinib-based combination treatments with other targeted inhibitors in oral squamous cell carcinoma. We determined the anti-proliferative effects of afatinib on a panel of oral squamous cell carcinoma cell lines using a crystal violet-growth inhibition assay, click-iT 5-ethynyl-2′-deoxyuridine staining, and cell-cycle analysis. Biochemical assays were performed to study the underlying mechanism of drug treatment as a single agent or in combination with the MEK inhibitor trametinib. We further evaluated and compared the anti-tumor effects of single agent and combined treatment by using oral squamous cell carcinoma xenograft models. In this study, we showed that afatinib inhibited oral squamous cell carcinoma cell proliferation via cell-cycle arrest at the G0/G1 phase, and inhibited tumor growth in xenograft mouse models. Interestingly, we demonstrated reactivation of the mitogen-activated protein kinase (ERK1/2) pathway in vitro, which possibly reduced the effects of ErbB inhibition. Concomitant treatment of oral squamous cell carcinoma cells with afatinib and trametinib synergized the anti-tumor effects in oral squamous cell carcinoma-bearing mouse models. Our findings provide insight into the molecular mechanism of resistance to afatinib and support further clinical evaluation into the combination of afatinib and MEK inhibition in the treatment of oral squamous cell carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink